The National Competition Council has formally endorsed the creation of “Sensyo Pharmatech,” a Moroccan company specialized in biotherapy that will accompany the production of COVID-19 vaccines in the country.
The authorization was published in the official bulletin this November 4, green lighting the Mohammed VI Fund for Investment company, listed in partnership with the Banking Consortium (BAB). The BAB groups Bank of Africa, BCP, Attijariwafa Bank, and Swedish group Recipharm.
Sensyo Pharmatech is created to set the stage for a national vaccine manufacturer Sothema and to accompany the realization of the project.
The first mission of the company will be to build the Fill and Finish unit, for which works are underway, as syringing will be the initial stage of Moroccan vaccine manufacturing, in partnership with a Chinese pharmaceuticals company, Sinopharm.
The project is supervised by Swedish subcontractor Recipharm, who will accompany the newly approved Moroccan operator in the construction and installation of the factory specialized in the filling technique.
Recipharm will, in addition to the transfer of know-how relating to manufacturing technology, train the Moroccan workforce and manage the plant for a fixed period before passing the torch to Moroccan managers. The new plant is expected to be fully operational by the end of 2022.
Morocco has set a five-year strategy to become capable of manufacturing several types of vaccines and aims to conclude partnerships with several scientific institutions to develop different types of vaccines, after mastering COVID-19 vaccine manufacturing processes.
add your comment
Terms of publication : Not to offend the writer, people, sacred things, or attack religions or the divine self, and refrain from racist incitement and insults.